NK cell phenotype and function in CML patients at diagnosis, pre-MMR, MMR, MR^4.5, TFR, and in healthy donors (HDs). (A) (i) CD3⁻CD56^brCD16^−/dim (immunoregulatory) and CD3⁻CD56^dimCD16^br (cytolytic) NK cell gating. (ii) Percent expression CD3⁻CD56^brCD16^−/dim and CD3⁻CD56^dimCD16^br NK cells as a proportion of total lymphocytes. (B) (i) CD57⁺CD62L⁻ NK cell gating. (ii) Percent expression CD57⁺CD62L⁻ (of total NK cells). (C) Representative dot plot of CD107a⁺ expression in CD3⁻CD56^dim NK cells (left) and percent CD107a⁺ NK cells in CML patients (of total lymphocytes). Bars denote the median. ***P ≤ .001; **P ≤ .01.